InvestorsHub on MSN
Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish
Shares of Replimune Group (NASDAQ:REPL) tumbled sharply in premarket trading on Monday, falling close to 60% after the U.S.
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
As shares of Replimune Group hit an all-time low on Monday of $1.50 following the US FDA's rejection of its lead asset, the ...
Stocktwits on MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays
Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...
An online coding platform called Repl.it is picking up popularity among kids and teenagers, who are using the platform to learn to code and to build apps online. Kids enjoy using Repl.it because they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results